CN102762550B - Xa因子抑制剂的盐和结晶形式 - Google Patents

Xa因子抑制剂的盐和结晶形式 Download PDF

Info

Publication number
CN102762550B
CN102762550B CN201080064120.8A CN201080064120A CN102762550B CN 102762550 B CN102762550 B CN 102762550B CN 201080064120 A CN201080064120 A CN 201080064120A CN 102762550 B CN102762550 B CN 102762550B
Authority
CN
China
Prior art keywords
compound
salt
crystalline form
crystalline
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080064120.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102762550A (zh
Inventor
A.潘戴
L.J.奎甘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN102762550A publication Critical patent/CN102762550A/zh
Application granted granted Critical
Publication of CN102762550B publication Critical patent/CN102762550B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080064120.8A 2009-12-17 2010-12-16 Xa因子抑制剂的盐和结晶形式 Expired - Fee Related CN102762550B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28768309P 2009-12-17 2009-12-17
US61/287,683 2009-12-17
PCT/US2010/060885 WO2011084652A2 (en) 2009-12-17 2010-12-16 Salts and crystalline forms of a factor xa inhibitor

Publications (2)

Publication Number Publication Date
CN102762550A CN102762550A (zh) 2012-10-31
CN102762550B true CN102762550B (zh) 2015-04-01

Family

ID=43618959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080064120.8A Expired - Fee Related CN102762550B (zh) 2009-12-17 2010-12-16 Xa因子抑制剂的盐和结晶形式

Country Status (6)

Country Link
US (1) US8530501B2 (https=)
EP (1) EP2513094B1 (https=)
JP (1) JP5796872B2 (https=)
CN (1) CN102762550B (https=)
CA (1) CA2784921A1 (https=)
WO (1) WO2011084652A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8742120B2 (en) * 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
AR079491A1 (es) 2009-12-17 2012-02-01 Millennium Pharm Inc Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
CN120633248B (zh) * 2025-08-08 2025-10-17 成都理工大学 超临界地热流体体系KCl-H2O的电导率计算方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1523986A (zh) * 2001-06-20 2004-08-25 �����ɷ� 用于联合治疗的取代的噁唑烷酮类化合物
WO2007025940A1 (de) * 2005-08-29 2007-03-08 Boehringer Ingelheim International Gmbh Substituierte biaryle und deren verwendung als faktor xa-inhibitoren
CN1968922A (zh) * 2004-06-18 2007-05-23 米伦纽姆医药公司 因子xa抑制剂
WO2007131179A1 (en) * 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CA2295620A1 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. 5,6-heteroaryl-dipyrido¬2,3-b:3',2'-f|azepines and their use in the prevention or treatment of hiv infection
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
JP2000178243A (ja) 1998-12-14 2000-06-27 Teijin Ltd ビフェニルアミジン誘導体
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
ATE368643T1 (de) 2001-03-30 2007-08-15 Millennium Pharm Inc Faktor xa benzamidin inhibitoren
US7312235B2 (en) 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
ES2180456B1 (es) 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
US6914058B2 (en) 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
JP4471262B2 (ja) 2002-03-07 2010-06-02 株式会社エス・ディー・エス バイオテック 置換イソキサゾールアルキルアミン誘導体及び農園芸用殺菌剤
US20070043079A1 (en) 2003-04-18 2007-02-22 Hiromu Habashita Heterocyclic compound containing nitrogen atom and use thereof
WO2004101531A1 (en) 2003-04-29 2004-11-25 Dr. Reddy's Laboratories Ltd. Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
WO2004106329A2 (en) 2003-06-03 2004-12-09 Dr. Reddy's Laboratories Ltd. Novel antiinfective compounds and their pharmaceutical compositions
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
US7022695B2 (en) 2003-10-09 2006-04-04 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of Factor Xa
WO2005035528A2 (en) 2003-10-14 2005-04-21 Dr. Reddy's Laboratories Ltd. Triazole derivatives as antibacterial agents
WO2005082892A2 (en) 2004-02-17 2005-09-09 Dr. Reddy's Laboratories Ltd. Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
PT1951254E (pt) 2005-11-03 2012-04-12 Portola Pharm Inc [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas
PE20070717A1 (es) 2005-11-08 2007-08-17 Millennium Pharm Inc Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
US20090186810A1 (en) 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
DE102006025314A1 (de) 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
US20080051578A1 (en) 2006-08-24 2008-02-28 Georg Dahmann Substituted biaryls, process for their manufacture and use thereof as medicaments
CN101595092B (zh) 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
KR101472765B1 (ko) 2006-12-08 2014-12-15 밀레니엄 파머슈티컬스 인코퍼레이티드 경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법
WO2008086226A2 (en) 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008121721A2 (en) 2007-03-28 2008-10-09 Portola Pharmaceuticals, Inc. Targeted delivery and expression of procoagulant hemostatic activity
EA020531B1 (ru) 2007-04-13 2014-11-28 Милленниум Фармасьютикалз, Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИКОАГУЛИРУЮЩЕГО СРЕДСТВА С СОЕДИНЕНИЕМ, КОТОРОЕ ДЕЙСТВУЕТ КАК ИНГИБИТОР ФАКТОРА Ха
KR101509829B1 (ko) 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
EP3121271B1 (en) 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1523986A (zh) * 2001-06-20 2004-08-25 �����ɷ� 用于联合治疗的取代的噁唑烷酮类化合物
CN1968922A (zh) * 2004-06-18 2007-05-23 米伦纽姆医药公司 因子xa抑制剂
WO2007025940A1 (de) * 2005-08-29 2007-03-08 Boehringer Ingelheim International Gmbh Substituierte biaryle und deren verwendung als faktor xa-inhibitoren
WO2007131179A1 (en) * 2006-05-05 2007-11-15 Millennium Pharmaceuticals, Inc. Factor xa inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Xa 因子抑制剂的药效团模型初探";王坚毅，等;《药学进展》;20031231;第27卷(第1期);第5-9页 *
"新型抗凝药物直接Xa因子抑制剂利伐沙班";柯永胜;《中国临床药理学与治疗学》;20090430;第14卷(第4期);第361-367页 *

Also Published As

Publication number Publication date
WO2011084652A3 (en) 2011-09-09
CA2784921A1 (en) 2011-07-14
JP5796872B2 (ja) 2015-10-21
US20110178135A1 (en) 2011-07-21
EP2513094A2 (en) 2012-10-24
JP2013514981A (ja) 2013-05-02
WO2011084652A2 (en) 2011-07-14
HK1177459A1 (zh) 2013-08-23
CN102762550A (zh) 2012-10-31
US8530501B2 (en) 2013-09-10
EP2513094B1 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
DK2906551T3 (en) CRYSTALLIC FORMS OF A FACTOR XIA INHIBITOR
KR101358574B1 (ko) Ｘａ 인자 억제제, ｎ­（5­클로로­2­피리디닐）­2­［［4­［（디메틸아미노）이미노메틸］벤조일］아미노］­5­메톡시­벤자마이드의 약제학적 염 및 다형체
CN103261161B (zh) 凝血因子Xa抑制剂的结晶形式
CN116262734A (zh) 新型氧代吡啶类化合物及其制备方法和用途
CN110291079A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
JP2000302765A (ja) 新規なジアゼパン誘導体又はその塩
CN102762550B (zh) Xa因子抑制剂的盐和结晶形式
EP1838716B1 (en) Olanzapine pamoate dihydrate
US20110160250A1 (en) Crystalline forms of a factor xa inhibitor
CN116262740A (zh) 新型氧代吡啶类化合物及其制备方法和用途
AU2005317158A1 (en) Crystalline forms of a factor Xa inhibitor
WO2006036927A1 (en) Crytalline forms of a pyrazolo `3, 4-c ! pyridine factor xa inhibitor
HK1177459B (en) Crystalline salts of a factor xa inhibitor
WO2026062171A1 (en) Pyridopyrimidine derivative as histamine receptor inhibitor
HK1212333B (en) Crystalline forms of a factor xia inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150401

Termination date: 20191216

CF01 Termination of patent right due to non-payment of annual fee